Top

Published in:

01-12-2021 | SARS-CoV-2 | Research Letter

Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients

Authors: Geoffroy Hariri, Tomas Urbina, Sandie Mazerand, Naike Bige, Jean-Luc Baudel, Hafid Ait-Oufella

Published in: Critical Care | Issue 1/2021

Excerpt

Atrial fibrillation (AF) is frequent in shock patients admitted to the intensive care unit (ICU) [1, 2] and is associated with increased mortality [1]. Several mechanisms are involved in the development of AF in the context of acute circulatory failure, including hypovolemia and β1-adrenergic stimulation in response to endogenous catecholamine production as well as norepinephrine infusion [3]. Atrial fibrillation impairs left ventricular filling and consecutively stroke volume, and in fine potentially aggravates circulatory failure. …

Steinberg I, Brogi E, Pratali L, Trunfio D, Giuliano G, Bignami E, Forfori F. Atrial fibrillation in patients with septic shock: a one-year observational pilot study. Turk J Anaesthesiol Reanim. 2019;47(3):213–9.CrossRef

Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bogelein D, Gauss A, et al. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit Care. 2010;14(3):R108.CrossRef

Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–8.CrossRef

Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth. 2001;48(10):985–9.CrossRef

Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, et al. Efficacy and safety of landiolol, an ultra-short-acting beta1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;9:863–72.CrossRef

Matsuishi Y, Mathis BJ, Shimojo N, Kawano S, Inoue Y. Evaluating the therapeutic efficacy and safety of landiolol hydrochloride for management of arrhythmia in critical settings: review of the literature. Vasc Health Risk Manag. 2020;16:111–23.CrossRef

Title: Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients
Authors: Geoffroy Hariri
Tomas Urbina
Sandie Mazerand
Naike Bige
Jean-Luc Baudel
Hafid Ait-Oufella
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: SARS-CoV-2
Atrial Fibrillation
Published in: Critical Care / Issue 1/2021
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-021-03470-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Plasma glutamine status at intensive care unit admission: an independent risk factor for mortality in critical illness

Effect of intra-arrest trans-nasal evaporative cooling in out-of-hospital cardiac arrest: a pooled individual participant data analysis

Development of a new score for early mortality prediction in trauma ICU patients: RETRASCORE

Implications of cardiac markers in risk-stratification and management for COVID-19 patients

Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs

Association between the use of balanced fluids and outcomes in critically ill children: a before and after study